Bli medlem
Bli medlem

Du är här


ObsEva SA: ObsEva SA to Attend LEERINK Partners Global Healthcare Conference in NYC

ObsEva SA / ObsEva SA to Attend LEERINK Partners Global Healthcare Conference
in NYC. Processed and transmitted by Nasdaq Corporate Solutions. The issuer
is solely responsible for the content of this announcement.
Geneva, Switzerland - February 03, 2017
- ObsEva SA (ObsEva) announced today that Ernest LOUMAYE, M.D., Ph.D., CEO and
Co-Founder and Tim ADAMS, CFO, will attend the LEERINK Partners Global
Healthcare Conference and hold one-on-one meetings on February 15 and 16,
2017 at Lotte New York Palace, NYC.

- ends -

About ObsEva SA

ObsEva is a clinical-stage biopharmaceutical company focused on the clinical
development and commercialization of novel therapeutics for serious
conditions that compromise a woman's reproductive health and pregnancy.
ObsEva is focused on providing therapeutic solutions for women between the
ages of 15 and 49 who suffer from reproductive health conditions that affect
their quality of life or ability to conceive, or that complicate pregnancy
and the health of newborns. Through strategic in-licensing and disciplined
drug development, ObsEva has established a late-stage clinical pipeline with
development programs focused on treating endometriosis, uterine fibroids,
preterm labor and improving in vitro fertilization outcomes. ObsEva is listed
on The NASDAQ Global Select Market and is trading under the ticker symbol
"OBSV". For more information, please


Liz Bryan
Spectrum Science

202-955-6222 x2526


Delphine Renaud
ObsEva, CEO Office

+41 22 552 1550

Press Release

This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: ObsEva SA via Globenewswire

Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.